LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Inicio・Lista de Acciones・MacroGenics Inc

MacroGenics Inc

Cerrado

SectorSanidad

4.45 -1.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.31

Máximo

4.53

Métricas clave
By Trading Economics
Ingresos	-23M -37M
Ventas	-20M 21M
BPA	-0.58
Margen de beneficios	-177.011
Empleados	293
EBITDA	-17M -32M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+39.74% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	100M 288M
Apertura anterior	6
Cierre anterior	4.45

Noticias sobre sentimiento de mercado

By Acuity

92%

5 / 344 Clasificación en Healthcare

MacroGenics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 may 2026, 16:52 UTC

Noticias de Eventos Importantes

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q Rev $1.76B >SQM

26 may 2026, 23:57 UTC

Ganancias

Sociedad Quimica 1Q EPS $1.28 >SQM

26 may 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q EPS $11.61 >WEBC

26 may 2026, 21:54 UTC

Ganancias

Webco Industries 3Q Sales $179.6M >WEBC

26 may 2026, 21:48 UTC

Charlas de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 may 2026, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

26 may 2026, 20:58 UTC

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

26 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 19:22 UTC

Charlas de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 may 2026, 19:17 UTC

Charlas de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 may 2026, 18:56 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 may 2026, 18:03 UTC

Charlas de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 may 2026, 17:42 UTC

Charlas de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 may 2026, 17:33 UTC

Charlas de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 may 2026, 17:21 UTC

Charlas de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 may 2026, 16:52 UTC

Charlas de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 may 2026, 16:43 UTC

Charlas de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 may 2026, 16:24 UTC

Charlas de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 may 2026, 16:21 UTC

Charlas de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

26 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

26 may 2026, 16:16 UTC

Charlas de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 may 2026, 16:01 UTC

Charlas de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 may 2026, 15:21 UTC

Charlas de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparación entre iguales

Cambio de precio

MacroGenics Inc previsión

Precio Objetivo

By TipRanks

39.74% repunte

Estimación a 12 Meses

Media 6.33 USD 39.74%

Máximo 9 USD

Mínimo 4 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MacroGenics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para MacroGenics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

5 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.